Cargando…
Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients
Anti-PD1 treatment has improved the survival of metastatic melanoma patients, yet it is unknown which patients benefit from the treatment. In this exploratory study, we aimed to understand the effects of anti-PD1 therapy on the patients’ immune system and discover the characteristics that would resu...
Autores principales: | Kasanen, Henna, Hernberg, Micaela, Mäkelä, Siru, Brück, Oscar, Juteau, Susanna, Kohtamäki, Laura, Ilander, Mette, Mustjoki, Satu, Kreutzman, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183505/ https://www.ncbi.nlm.nih.gov/pubmed/32036449 http://dx.doi.org/10.1007/s00262-020-02497-9 |
Ejemplares similares
-
Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma
por: Huuhtanen, Jani, et al.
Publicado: (2023) -
High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma
por: Kohtamäki, Laura, et al.
Publicado: (2021) -
IFNα induces prolonged remissions modeling curative immunologic responses in chronic myeloid leukemia
por: Ilander, Mette, et al.
Publicado: (2014) -
Evolution and modulation of antigen-specific T cell responses in melanoma patients
por: Huuhtanen, Jani, et al.
Publicado: (2022) -
Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma
por: Chiaro, Jacopo, et al.
Publicado: (2021)